stockportfolio.pro
Stocks / OCUL vs ZLAB
OCUL vs ZLAB
Ocular Therapeutix, Inc. and Zai Lab Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Ocular Therapeutix, Inc. (OCUL) | Zai Lab Limited (ZLAB) | |
|---|---|---|
| Market cap | $1.9B | $1.9B |
| Revenue (latest FY) | $51.95M | $460.16M |
| Net income (latest FY) | $-265.94M | $-175.54M |
| Revenue growth (5y CAGR) | 24.4% | 56.5% |
| Net margin | -511.9% | -38.1% |
| Return on equity | -40.6% | -24.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open OCUL — free Open ZLAB — freeFrequently asked questions
Which is bigger, OCUL or ZLAB?
Zai Lab Limited is larger by market capitalization — $1.9B versus $1.9B.
Which grows faster, OCUL or ZLAB?
Over the last five fiscal years, Zai Lab Limited grew revenue faster — 56.5%/yr versus 24.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.